Published in J Biol Chem on August 23, 2012
Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Sci Transl Med (2013) 1.62
Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc (2013) 1.15
Invertebrate extracellular phagocyte traps show that chromatin is an ancient defence weapon. Nat Commun (2014) 0.89
Stable Redox-Cycling Nitroxide Tempol Inhibits NET Formation. Front Immunol (2012) 0.88
Activated microglia mediate synapse loss and short-term memory deficits in a mouse model of transthyretin-related oculoleptomeningeal amyloidosis. Cell Death Dis (2013) 0.84
Alzheimer's associated β-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS One (2014) 0.82
A Metabolic Shift toward Pentose Phosphate Pathway Is Necessary for Amyloid Fibril- and Phorbol 12-Myristate 13-Acetate-induced Neutrophil Extracellular Trap (NET) Formation. J Biol Chem (2015) 0.79
Neutrophil extracellular traps release induced by Leishmania: role of PI3Kγ, ERK, PI3Kσ, PKC, and [Ca2+]. J Leukoc Biol (2016) 0.78
Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease. J Exp Med (2014) 0.78
Crystallins and neuroinflammation: The glial side of the story. Biochim Biophys Acta (2015) 0.76
NETosis in Alzheimer's Disease. Front Immunol (2017) 0.75
The "Jekyll and Hyde" Actions of Nucleic Acids on the Prion-like Aggregation of Proteins. J Biol Chem (2016) 0.75
Conservative Mechanisms of Extracellular Trap Formation by Annelida Eisenia andrei: Serine Protease Activity Requirement. PLoS One (2016) 0.75
Peptidylarginine deiminase 4 promotes age-related organ fibrosis. J Exp Med (2016) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Neutrophil extracellular traps kill bacteria. Science (2004) 23.64
Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem (2006) 22.87
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol (2006) 12.29
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature (2002) 10.81
Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med (2009) 6.72
Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A (2010) 5.69
Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med (2011) 5.60
Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog (2009) 5.40
Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A (2010) 5.05
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med (2011) 4.51
An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr Biol (2006) 3.69
Amyloidosis. Annu Rev Med (2006) 3.27
NETs: a new strategy for using old weapons. Trends Immunol (2009) 2.98
Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc Natl Acad Sci U S A (2009) 2.68
Techniques to study amyloid fibril formation in vitro. Methods (2004) 2.65
Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem (1997) 2.62
Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. Cell Death Differ (2011) 2.60
Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging (2006) 2.50
Nuclease expression by Staphylococcus aureus facilitates escape from neutrophil extracellular traps. J Innate Immun (2010) 2.34
Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol (2002) 2.26
Fibril fragmentation enhances amyloid cytotoxicity. J Biol Chem (2009) 2.13
Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci (2006) 1.89
Analysis of prion factors in yeast. Methods Enzymol (2002) 1.72
Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry (1998) 1.72
Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci (1998) 1.68
Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann N Y Acad Sci (2000) 1.67
Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol (2000) 1.66
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med (2008) 1.48
The clinical value of neutrophil extracellular traps. Med Microbiol Immunol (2009) 1.34
Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol (2011) 1.32
Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal (2011) 1.29
Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. Trans Assoc Am Physicians (1983) 1.24
Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest (2003) 1.10
Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration. J Neurochem (2007) 0.97
Fibril protein fragmentation pattern in systemic AL-amyloidosis. J Pathol (2009) 0.94
Methods for staining amyloid in tissues: a review. Stain Technol (1988) 0.94
Effects of extracellular DNA on plasminogen activation and fibrinolysis. J Biol Chem (2011) 0.92
The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. J Mol Biol (2010) 0.90
Immunology. The tangled webs that neutrophils weave. Science (2004) 0.90
Characterization of high molecular weight amyloid A proteins. Scand J Immunol (1991) 0.89
The yeast prion [PSI+]: molecular insights and functional consequences. Adv Protein Chem (2001) 0.87
Serum amyloid A protein in mink during endotoxin induced inflammation and amyloidogenesis. Scand J Immunol (1994) 0.87
Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases. J Biol Chem (2008) 0.83
Bovine glomerular amyloidosis: morphological studies. Zentralbl Veterinarmed A (1994) 0.80
Neutrophil proteases associated with amyloid fibrils. Biochem Biophys Res Commun (1993) 0.78
A fluorescent mutant of the NM domain of the yeast prion Sup35 provides insight into fibril formation and stability. Biochemistry (2009) 0.77
Elastase digestion of the amyloid-like substance surrounding mammary cancer and basal cell carcinoma of the skin. Acta Derm Venereol (1973) 0.76
Adapting proteostasis for disease intervention. Science (2008) 13.22
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Opposing activities protect against age-onset proteotoxicity. Science (2006) 5.85
Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem (2009) 5.23
Semen-derived amyloid fibrils drastically enhance HIV infection. Cell (2007) 5.23
Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell (2006) 5.01
Therapeutic approaches to protein-misfolding diseases. Nature (2003) 4.57
Functional amyloid--from bacteria to humans. Trends Biochem Sci (2007) 4.50
Functional amyloid formation within mammalian tissue. PLoS Biol (2006) 3.92
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell (2008) 3.11
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell (2009) 2.87
The biological and chemical basis for tissue-selective amyloid disease. Cell (2005) 2.76
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A (2002) 2.71
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol (2009) 2.70
Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc Natl Acad Sci U S A (2009) 2.68
Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science (2003) 2.63
An experimental survey of the transition between two-state and downhill protein folding scenarios. Proc Natl Acad Sci U S A (2008) 2.57
Context-dependent contributions of backbone hydrogen bonding to beta-sheet folding energetics. Nature (2004) 2.44
Structure-function-folding relationship in a WW domain. Proc Natl Acad Sci U S A (2006) 2.28
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res (2005) 2.25
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A (2002) 2.25
Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. ACS Chem Biol (2006) 2.25
Tuning the free-energy landscape of a WW domain by temperature, mutation, and truncation. Proc Natl Acad Sci U S A (2003) 2.15
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14
Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry (2004) 2.08
Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol (2011) 2.08
Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep (2013) 1.87
An adaptable standard for protein export from the endoplasmic reticulum. Cell (2007) 1.86
ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization. J Mol Biol (2003) 1.82
Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem Biol (2004) 1.76
Intriguing nucleic-acid-binding features of mammalian prion protein. Trends Biochem Sci (2008) 1.74
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A (2013) 1.73
Determinants for dephosphorylation of the RNA polymerase II C-terminal domain by Scp1. Mol Cell (2006) 1.71
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol (2005) 1.68
Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov (2002) 1.63
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol (2010) 1.62
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med (2011) 1.62
Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol (2006) 1.60
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem (2007) 1.58
Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.55
Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des (2008) 1.55
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem (2004) 1.54
The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proc Natl Acad Sci U S A (2009) 1.54
Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state. Biochemistry (2008) 1.51
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest (2004) 1.50
Engineering a beta-sheet protein toward the folding speed limit. J Phys Chem B (2005) 1.49
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol (2008) 1.42
Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol (2011) 1.41
A fundamental protein property, thermodynamic stability, revealed solely from large-scale measurements of protein function. Proc Natl Acad Sci U S A (2012) 1.39
Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl (2003) 1.39
Localized thermodynamic coupling between hydrogen bonding and microenvironment polarity substantially stabilizes proteins. Nat Struct Mol Biol (2009) 1.37
D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry (2003) 1.36
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid (2006) 1.34
The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry (2005) 1.32
Heparin accelerates gelsolin amyloidogenesis. Biochemistry (2006) 1.31
Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J (2007) 1.29
N-terminal domains elicit formation of functional Pmel17 amyloid fibrils. J Biol Chem (2009) 1.28
Protein native-state stabilization by placing aromatic side chains in N-glycosylated reverse turns. Science (2011) 1.27
Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry (2005) 1.26
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A (2003) 1.26
Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem (2012) 1.26
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry (2008) 1.26
Toward assessing the position-dependent contributions of backbone hydrogen bonding to beta-sheet folding thermodynamics employing amide-to-ester perturbations. J Am Chem Soc (2004) 1.26
Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis. Nat Chem Biol (2010) 1.26
Toward quantification of protein backbone-backbone hydrogen bonding energies: An energetic analysis of an amide-to-ester mutation in an alpha-helix within a protein. Protein Sci (2008) 1.26
The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry (2007) 1.25
NMR solution structure of the isolated Apo Pin1 WW domain: comparison to the x-ray crystal structures of Pin1. Biopolymers (2002) 1.24
Probing the folding transition state structure of the villin headpiece subdomain via side chain and backbone mutagenesis. J Am Chem Soc (2009) 1.23
Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry (2003) 1.22
Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem (2002) 1.22
ETosis: A Microbicidal Mechanism beyond Cell Death. J Parasitol Res (2012) 1.22
Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res (2006) 1.20
Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem (2005) 1.19
Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc (2005) 1.18
X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. J Biol Chem (2005) 1.18
Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem (2007) 1.17
Backbone-Backbone H-Bonds Make Context-Dependent Contributions to Protein Folding Kinetics and Thermodynamics: Lessons from Amide-to-Ester Mutations. Adv Protein Chem (2005) 1.16
Influence of the N-terminal domain on the aggregation properties of the prion protein. Protein Sci (2005) 1.16
Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc (2013) 1.15
The effect of backbone cyclization on the thermodynamics of beta-sheet unfolding: stability optimization of the PIN WW domain. J Am Chem Soc (2002) 1.15
Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. J Mol Biol (2005) 1.14
Discovery and characterization of a mammalian amyloid disaggregation activity. Protein Sci (2010) 1.13
Temporal requirements of insulin/IGF-1 signaling for proteotoxicity protection. Aging Cell (2009) 1.13
Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci U S A (2005) 1.12
Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J Am Chem Soc (2003) 1.12
Small molecule oxidation products trigger disease-associated protein misfolding. Acc Chem Res (2006) 1.11
A biomimetic synthesis of thiazolines using hexaphenyloxodiphosphonium trifluoromethanesulfonate. Angew Chem Int Ed Engl (2003) 1.11
Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest (2003) 1.10
Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem (2008) 1.10
Recombinant expression, purification, and comparative characterization of torsinA and its torsion dystonia-associated variant Delta E-torsinA. Biochemistry (2003) 1.10
Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. J Mol Biol (2008) 1.08
Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry (2003) 1.08
Biochemical properties of highly neuroinvasive prion strains. PLoS Pathog (2012) 1.07
Evaluating beta-turn mimics as beta-sheet folding nucleators. Proc Natl Acad Sci U S A (2009) 1.07
Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins. Acc Chem Res (2010) 1.06
Amide-to-E-olefin versus amide-to-ester backbone H-bond perturbations: Evaluating the O-O repulsion for extracting H-bond energies. J Am Chem Soc (2006) 1.06